Purchase Order 75N95020P00740
- Not listed
- The National Institute on Drug Abuse (NIDA), on behalf of the National Center for Advancing Translational Sciences (NCATS), awarded a $209,264.57 firm-fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. for induced pluripotent stem (iPS) cell-derived differentiated cells. The cells will be used for research projects related to health. The contract is non-competitive and does not have a small business set-aside designation. Fujifilm Cellular Dynamics, Inc. is a foreign-owned,...
- This is a $24,061 firm-fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, to the foreign-owned, for-profit manufacturer Fujifilm Cellular Dynamics, Inc. The contract is for the supply of various induced pluripotent stem cell (iPSC)-derived human cell products, including cardiomyocytes, neurons, astrocytes, hepatocytes, and endothelial cells. These specialized cell lines are used in biomedical...
- This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc. for induced pluripotent stem (iPS) cell-derived differentiated cells. The $241,459.53 contract is for the supply of various iPS cell-derived cell types, including dopaminergic, GABAergic, and glutamatergic neurons, as well as endothelial cells, to support the National Center for Advancing...
- This federal contract award is to Fujifilm Cellular Dynamics, Inc., a subsidiary of the Fuji Photo Film Company LIMITED, for the provision of induced pluripotent stem cell-derived human cell products. The contract, valued at $11,080, was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services. The contract is a firm-fixed-price Blanket Purchase Agreement (BPA) call, and does not have a small business set-aside designation....
- This purchase order awards Fujifilm Cellular Dynamics, Inc. $349,700 for induced pluripotent stem (iPS) cell-derived differentiated cells to support the National Center for Advancing Translational Sciences within the National Institutes of Health's National Institute on Drug Abuse. The contract delivers over 300 units of various iPS cell-derived differentiated cells to develop three-dimensional tissue models of the brain. A pre-solicitation notice sought capability statements for a potential...
- This is a $124,070 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell (iPSC) derived human cell products. The contract is for the delivery of iPSC-derived human neurons and astrocytes, which are biologically relevant cell types used to support biomedical...
- This is a firm-fixed-price purchase order awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian agency within the Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a subsidiary of Fuji Photo Film Company LIMITED. The $18,195 contract is for the supply of induced pluripotent stem cell-derived human cardiomyocytes (iCell Cardiomyocytes). This specialized cellular product supports critical research initiatives, including drug development,...
- This is a $23,906 firm fixed price purchase order awarded to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The award is from the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services. The contract is for the delivery of various iPSC-derived cell types, such as...
- This $16,375.00 firm-fixed-price purchase order was awarded by the National Heart Lung and Blood Institute, a component of the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned manufacturer of specialized human cell cultures derived from induced pluripotent stem cells (iPSCs). The contract is for the delivery of iCell Cardiomyocytes, which are biologically relevant human cardiac cells used to support biomedical research and drug development...
- This firm-fixed-price purchase order was awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services (HHS), to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell lines. The $79,500.00 contract is for the supply of iCell Cardiomyocytes, a specialized cell product used in biomedical research and drug development. This contract is not set aside for small...
The National Institute on Drug Abuse (NIDA) awarded a $243,259 firm fixed-price purchase order to Fujifilm Cellular Dynamics, Inc., a subsidiary of Japan-based Fuji Photo Film Company LIMITED, on September 25, 2020. The contract calls for the supply of induced pluripotent stem (IPS) cell-derived differentiated cells, with performance to be completed in Madison, Wisconsin by October 16, 2020. This award was issued to de-obligate remaining expiring fiscal year funding and was not subject to a small business set-aside designation. Fujifilm Cellular Dynamics specializes in producing biologically relevant human cells derived from iPSCs for biomedical research and drug development applications. The company's federal contract portfolio demonstrates consistent engagement with civilian research agencies, particularly within the Department of Health and Human Services, supplying highly specialized and proprietary cell lines including cardiomyocytes, neurons, hepatocytes, and other differentiated cell types. This purchase order aligns with NIDA's research mission and represents a typical engagement with this vendor, whose cellular products support critical drug development and toxicology screening initiatives across federal research institutions.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
iCell and MyCell induced pluripotent stem (iPS) cell-derived differentiated cells | 75N95020Q00314 | Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse | Solicitation 1/1 | 9/8/20, 3:28 PM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Funding Only Action | ($1) | 9/2/25 | |
| P00001 | Supplemental Agreement for work within scope | $0 | 6/13/22 | |
| Not listed | Not listed | $243.3k | 9/25/20 |